SmartNuclide Overview

  • Founded
  • 2015

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $15.5M

  • Investors
  • 13

SmartNuclide General Information


Developer and researcher of biopharmaceuticals for molecular nuclear oncology. The company specializes in developing innovative biological drug products including both diagnostics and therapeutics formulations targeting molecular oncology, providing reliable and effective products for better cancer treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 218 Xinghu Street, BioBAY A4-202
  • Suzhou Industrial Park
  • Suzhou, Jiangsu
  • China

SmartNuclide Timeline

Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SmartNuclide Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 05-Jul-2021 $15.5M 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 23-Apr-2020 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 08-Mar-2018 Completed Startup
1. Seed Round 21-Mar-2016 Completed Startup
To view SmartNuclide’s complete valuation and funding history, request access »

SmartNuclide Executive Team (2)

Name Title Board Seat Contact Info
Tao Xu Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

SmartNuclide Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ABCI Securities Investment Bank Minority 000 0000 000000 0
Ciit Asset Management Asset Manager Minority 000 0000 000000 0
Qirong Venture Capital Venture Capital Minority 000 0000 000000 0
Tasly Capital Corporate Venture Capital Minority 000 0000 000000 0
Furong Capital Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »